ICE (chemotherapy)

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

ICE in the context of chemotherapy is an acronym for one of the chemotherapy regimens, used in salvage treatment of relapsed or refractory non-Hodgkin's lymphoma and Hodgkin lymphoma.

In case of CD20-positive B cell lymphoid malignancies the ICE regimen is often combined today with rituximab. This regimen is then called ICE-R or R-ICE or RICE.

[R]-ICE regimen consists of:

  1. (R)ituximab - an anti-CD20 monoclonal antibody, which is able to kill both normal and malignant CD20-bearing B cells;
  2. (I)fosfamide - an alkylating antineoplastic agent of the oxazafosforine group;
  3. (C)arboplatin - a platinum-based antineoplastic drug, also an alkylating antineoplastic agent;
  4. (E)toposide - a topoisomerase inhibitor.

Dosing regimen[edit]

Drug Dose Mode Days
(R)ituximab 375 mg/m2 IV infusion Day 1
(I)fosfamide 5000 mg/m2 IV continuous infusion over 24 hours Day 2
Mesna for haemorrhagic cystitis prophylaxis with ifosfamide 5000 mg/m2 IV continuous infusion over 24 hours Day 2
(C)arboplatin Optimized to get AUC = 5 (max. 800 mg) IV infusion Day 2
(E)toposide 100 mg/m2 IV infusion over 1 hour Days 1-3
Filgrastim to shorten the period of neutropenia 5 µg/kg S.C. Days 5-12

Cycles are repeated every 14 days for 3 cycles, then high-dose chemotherapy with autologous stem-cell transplantation follows (if the patient is considered eligible for HDCT and ASCT).[1][2]

References[edit]